Your browser doesn't support javascript.
loading
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.
Hoskin, Peter J; Kirkwood, Amy A; Popova, Bilyana; Smith, Paul; Robinson, Martin; Gallop-Evans, Eve; Coltart, Stewart; Illidge, Timothy; Madhavan, Krishnaswamy; Brammer, Caroline; Diez, Patricia; Jack, Andrew; Syndikus, Isabel.
Afiliação
  • Hoskin PJ; Mount Vernon Cancer Centre, Northwood, Middlesex, UK. Electronic address: peterhoskin@nhs.net.
  • Kirkwood AA; Cancer Research UK and UCL Cancer Trials Centre, London, UK.
  • Popova B; Cancer Research UK and UCL Cancer Trials Centre, London, UK.
  • Smith P; Cancer Research UK and UCL Cancer Trials Centre, London, UK.
  • Robinson M; Weston Park Hospital, Sheffield, UK.
  • Gallop-Evans E; Velindre Hospital, Cardiff, UK.
  • Coltart S; Kent and Canterbury Hospital, Canterbury, UK.
  • Illidge T; Christie Hospital, Manchester, UK.
  • Madhavan K; Southend General Hospital, Southend, UK.
  • Brammer C; New Cross Hospital, Wolverhampton, West Midlands, UK.
  • Diez P; Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
  • Jack A; Leeds General Infirmary, Leeds, UK.
  • Syndikus I; Clatterbridge Centre for Oncology, WirralI, UK.
Lancet Oncol ; 15(4): 457-63, 2014 Apr.
Article em En | MEDLINE | ID: mdl-24572077
BACKGROUND: Follicular lymphoma has been shown to be highly radiosensitive with responses to doses as low as 4 Gy in two fractions. This trial was designed to explore the dose response for follicular lymphoma comparing 4 Gy in two fractions with 24 Gy in 12 fractions METHODS: FORT is a prospective randomised, unblinded, phase 3 non-inferiority study comparing radiotherapy given as 4 Gy in two fractions with a standard dose of 24 Gy in 12 fractions. Entry criteria included all patients aged over 18 years, having local radiotherapy for radical or palliative local control, with follicular lymphoma or marginal zone lymphoma, who had received no previous treatment for at least 1 month before. The primary outcome was time to local progression analysed on an intention-to-treat basis. Randomisation was centralised through the Cancer Research UK and University College London Cancer Trials Centre. Radiotherapy target sites were randomised (1:1) with minimisation stratified by histology (follicular lymphoma vs marginal zone lymphoma), treatment intent (palliative or curative) and centre. This trial is registered with ClinicalTrials.gov number, NCT00310167. FINDINGS: 299 sites were randomly assigned to 24 Gy and 315 sites to 4 Gy between April 7, 2006, and June 8, 2011, at 43 centres in the UK. After a median follow-up of 26 months (range 0·39-75·4), 91 local progressions had been recorded (21 in the 24 Gy group and 70 in the 4 Gy group). Time to local progression with 4 Gy was not non-inferior to 24 Gy (hazard ratio 3·42, 95% CI 2·09-5·55, p<0·0001). Eight (3%) of 282 patients in the 24 Gy group and four (1%) of 300 in the 4 Gy group had acute grade 3-4 toxic effects. Four (1%) patients in the 24 Gy group and four (1%) patients in the 4 Gy group had late toxic effects. Mucositis was the most common event in the 24 Gy group (two patients with acute mucositis and two with late mucositis; all grade 3) and was not reported in the 4 Gy group. The most common acute effect was pain at the site of irradiation (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3), and the most common late effect was fatigue (two patients in the 4 Gy group, one patient in the 24 Gy group; all grade 3). INTERPRETATION: 24 Gy in 12 fractions is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard of care. However, 4 Gy remains a useful alternative for palliative treatment. FUNDING: Cancer Research UK.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dosagem Radioterapêutica / Linfoma Folicular Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dosagem Radioterapêutica / Linfoma Folicular Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2014 Tipo de documento: Article